Sign inJoin waitlistJoin the waitlist

Norman Wolmark

Director, National Cancer Institute Cooperative Group Clinical Trials, UPMC Hillman Cancer Center · UPMC Medical Education

Credentials: · · ·

History

National Cancer Institute Cooperative Group Clinical Trials Center · UPMC Medical Education
Present
UPMC Medical Education
Present

Complex General Surgical Oncology
Memorial Sloan Kettering Cancer Center
1977–1979
National Cancer Institute
McGill University
1970–1977
MCGILL UNIV, MONTREAL
1966–1970

Research

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
New England Journal of Medicine · 2004 · Last of 15 authors · 4,735 citations
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer
New England Journal of Medicine · 2002 · Last of 8 authors · 4,595 citations
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
New England Journal of Medicine · 2005 · Last of 25 authors · 4,152 citations

EM
Eleftherios Mamounas
113 papers
DW
Donald Wickerham
89 papers
Charles Geyer
84 papers
Priya Rastogi
58 papers
EF
Edwin Fisher
50 papers
SS
Sandra Swain
43 papers
TJ
Thomas Julian
43 papers
LF
Louis Fehrenbacher
41 papers
Patricia Ganz
29 papers
JA
James Atkins
28 papers
ND
Nikolay Dimitrov
26 papers
CA
Carmen Allegra
24 papers

Grants

NRG Oncology Network Group Operations Center
National Cancer Institute · U10
Contact PI · $193.6M · Nrg Oncology Foundation, Inc.
2014–2032
Nsabp Community Clinical Oncology Program Research Base - Operations Center
National Cancer Institute · U10
Contact PI · $152.4M · Nsabp Foundation, Inc.
1983–2016
NSABP Biological Specimen Banks
National Cancer Institute · U24
Contact PI · $9.4M · Nsabp Foundation, Inc.
2005–2015
National Surgical Adjuvant Breast and Bowel Project
National Cancer Institute · U10
Contact PI · $136.4M · Nsabp Foundation, Inc.
1976–2014

Clinical trials

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Principal investigator · Active not recruiting · Phase 3
NRG Oncology
2023–2037
A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy
Principal investigator · Withdrawn · Phase 2
NSABP Foundation Inc
2022–2027
Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients
Principal investigator · Unknown · Phase 1
NSABP Foundation Inc
2019–2022
Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer
Principal investigator · Unknown · Phase 2
NuGenerex Immuno-Oncology
2019–2024